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Abstract
Introduction Attention-deficit/hyperactivity disorder
(ADHD) is a neurobehavioral disorder characterized by
inattention, impulsivity, and hyperactivity, the levels of
which are inappropriately high for an individual’s devel-
opmental age.
Objective The objective of this study was to explore the
unmet needs of children/adolescents with ADHD and their
caregivers in eight European countries.
Methods Semi-structured interviews with 38 caregiv-
ers of children/adolescents (aged 6–17 years) with
ADHD and no or less serious comorbidities and 28
adolescents (aged 13–17 years) with ADHD and no or
less serious comorbidities were conducted, audio-
recorded, transcribed into English, and coded for
analysis.
Results Caregivers reported their own ADHD-related
issues, including making personal accommodations, such
as limiting activities and spending extra time/effort caring
for their child/adolescent, social impacts, and strained
relationships. Medication was generally considered help-
ful; however, most children experience core ADHD
symptoms while on medication (reported by 88 % of
caregivers and 100 % of adolescents). Adolescents often
reported schoolwork difficulties (96 %) and peer issues
(75 %), while caregivers reported school issues (84 %) and
peer difficulties (79 %). Caregivers reported minimal
ADHD education and community support. Caregivers
(29 %) and adolescents (54 %) desired medication that
better controlled symptoms but had concerns about being
oversubdued. Caregivers reported concerns about adverse
effects (21 %).
Conclusions European caregivers of children/adolescents
with ADHD identified multiple unmet needs, which persist
despite treatment. Adolescents noted impacts on school and
social interactions consistent with caregivers. Future
research is needed to quantify the study findings, and,
ultimately, ease the impact of ADHD on patients and their
caregivers.
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Key Points for Decision Makers
Unmet needs in children with attention-deficit/
hyperactivity disorder (ADHD) with no or less
serious comorbidities persist across Europe despite
medical treatment; patients struggle with symptoms,
school, and peer difficulties.
The burden of caring for a child with ADHD with no
or less serious comorbidities is substantial, leading to
strained relationships and various means of adjusting
and coping, while receiving minimal community
support.
Medication alleviates some symptoms and burden,
but concerns about being overly subdued and adverse
effects remain among both adolescents and
caregivers.
1 Background
Attention-deficit/hyperactivity disorder (ADHD) is a neu-
robehavioral disorder characterized by the combination of
three primary symptoms: inattention, impulsivity, and
hyperactivity, the levels of which are inappropriately high
for the individual’s developmental age. Prevalence estimates
for ADHD in Europe range from 1.5 to 8 %, as defined by
the ICD-10 or by the DSM-IV, respectively [1–3].
Best practice guidelines for the diagnosis and treatment
of ADHD in Europe have been provided by organizations
such as The National Institute for Health and Care Excel-
lence (NICE), the European Society for Child and Ado-
lescent Psychiatry (ESCAP), the Deutsche Gesellschaft fu¨r
Kinder- und Jugendpsychiatrie (DGKJP), and the Health
Ministry of Spain [4–6]. Guidelines generally suggest the
use of methylphenidate for initial pharmacologic treatment,
if indicated. Other possible pharmacologic treatments,
including the non-stimulant atomoxetine, are prescribed
depending on factors such as the presence of comorbidities,
experience of adverse effects, and parent/child preferences.
NICE, ESCAP, and DGKJP recommend that pharmaco-
logic treatment be part of a multi-disciplinary interven-
tional approach that includes educational and
psychological components.
A number of studies describe the burden of living with
ADHD [7–11]. ADHD can impact many aspects of a
child’s life, including school performance, social interac-
tions, family life, and emotional well-being [12]. Some
studies note that ADHD not only affects the patient, but
may have a substantial impact on the immediate family
[13–15]. While behavioral and medical therapy may help
to reduce ADHD symptoms, it is not well understood to
what degree unmet needs persist, despite current treatment
options and the standard of care that children/adolescents
with ADHD receive in Europe.
Qualitative research is a robust method of exploring
complex issues in depth and comprehensively [16]. The
open-ended nature of qualitative interviews allows for a
rich data set to be generated in the words of those directly
impacted. Qualitative data can be used not only to deepen
the understanding of an issue, but also to develop a com-
prehensive quantitative survey instrument to gather addi-
tional insights on the frequency with which issues occur
among a larger sample.
The objective of this study was to identify quantifiable
concepts of unmet need affecting children/adolescents with
ADHD and their caregivers in selected EU countries.
Specifically, the study explored qualitatively, through
open-ended interviews, the effects of ADHD and currently
available treatments in the EU (including pharmacologic
and non-pharmacologic) on the daily life of patients and
caregivers in an attempt to identify unmet needs. This
study aimed to generate concepts related to unmet need
that would help inform the development of a patient-cen-
tered web-based caregiver survey to further validate and
quantify those identified unmet needs for this population.
This approach to survey development is consistent with the
US Food and Drug Administration guidance on the
development of patient-reported instruments [17].
2 Methods
This was a cross-sectional study involving one-time inter-
views both the caregivers of children/adolescents (aged
6–17 years) with ADHD and adolescents (aged
13–17 years) with ADHD. The study was reviewed and
approved by a central institutional review board: MaGil
IRB, Rockville, MD, USA; the study was performed in
accordance with ethical standards laid down in the 1964
(and later amendments) Declaration of Helsinki. Study
participants resided in France, Germany, Italy, the
Netherlands, Norway, Spain, Sweden, and the UK.
Potentially eligible participants, recruited through online
panels of patients who had signed up to receive information
on studies for which they may qualify, were sent stan-
dardized email invitations with a link to an online
screening form. To be eligible for the study, the child/
adolescent with ADHD had to be diagnosed at least
6 months prior to screening. The adolescent participants
had to be aged 13–17 years, and the caregivers had to have
a child/adolescent with ADHD who was aged 6–17 years.
Caregiver/adolescent dyads (i.e., where both the caregiver
and his/her adolescent would participate in interviews)
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were allowed but not required. All interviews occurred
independently, including dyads. Identification of any
comorbid condition in the child/adolescent with ADHD
was a criterion for exclusion to minimize influencing fac-
tors of such conditions. However, because ADHD is highly
comorbid, it became difficult to meet recruitment targets in
a timely manner, so this criterion was removed prior to any
interviews. Patients with few or no comorbid conditions
and conditions that were deemed by the research team to be
less severe and less related to the ADHD, such as learning,
speech, sleep, or oppositional defiant disorder, were pref-
erentially selected over patients with comorbidities where
ADHD unmet need concepts could potentially be confused
with other severe comorbidities, such as autism, bipolar
disorder, or schizophrenia. Additionally, a diverse sample
with respect to age, sex, and treatment experience was
sought. As certain portions of the ADHD population are
typically under-represented in studies of ADHD, we
oversampled to ensure representation of adolescent female
individuals and children/adolescents taking the non-stim-
ulant atomoxetine hydrochloride (Strattera, Eli Lilly and
Company, Indianapolis, IN, USA). As such, if a caregiver
had more than one eligible child with ADHD, priority was
given to the child who would increase the representative-
ness of the sample with regard to age, sex, and treatment
experience, and with no or fewer comorbidities.
One-on-one telephone interviews were conducted by
experienced interviewers in the participant’s native lan-
guage. Participants in the UK were interviewed by members
of the research team with extensive qualitative interview
experience. Non-English interviews were conducted by
interviewers experienced in market research who were
native speakers of the language in which the interviews were
conducted. To ensure standardization and harmonization of
interviewers and techniques, a 1-day training seminar that
included mock interviews was held with all interviewers.
Each participant was asked to provide the appropriate
informed verbal consent and/or assent approved for the
study. Each interview followed a standardized semi-struc-
tured interview guide, which was designed based on previ-
ous ethnographic market research and feedback from three
EU clinical experts in ADHD, to elicit caregiver and ado-
lescent perspectives of ADHD impacts and treatment. The
interview began with open-ended questions to avoid limiting
input from patients and caregivers and to avoid researcher
bias in identifying unmet need. Participants were asked
questions about symptoms and behaviors, and asked to
compare on and off treatment experiences. Caregivers were
also asked about the impact of having a child with ADHD
on their own life. Caregiver interviews lasted 60–90 min and
adolescent interviews lasted 30–60 min. Interviews were
audio-recorded and subsequently transcribed into English.
Both cohorts were remunerated the equivalent of £25 in
local currency.
2.1 Analysis
All transcripts were translated into English and a content
and thematic analysis was performed to identify key
themes that emerged from the interviews [18]. Four
researchers trained in qualitative analysis coded the data
using MaxQDA 10 (VERBI GmbH, Germany), a qualita-
tive software analysis program. A code system was
developed, and the four coders met frequently to discuss
the identified themes, come to a consensus on any variance
in coding, and revise the code system as needed. The
coding was cross-checked for consistency and accuracy in
the application of codes. In addition, transcripts of care-
giver/adolescent dyads were compared using the coding
system to determine the general level of agreement with
respect to elicited concepts between the caregiver and their
adolescent. Specifically, codes applied to the transcripts of
the caregiver and corresponding adolescent were compared
to identify overlap in elicited concepts.
2.1.1 Assessment of Saturation
An examination of information saturation, or the point at
which no new information is collected with additional
interviews, was examined by reviewing the application of
codes. Evidence that saturation was obtained and the
sample size was sufficient was supported when no new
codes were being applied to the transcripts. Saturation was
attained in both sample groups. For the caregiver inter-
views (N = 38), 85 % of codes were assigned by the end
of the 15th interview, and 95 % by the end of the 27th
interview. No new codes were applied in the last two
interviews. For the adolescent interviews (N = 28), 84 %
of codes were assigned by the end of the 17th interview,
and 96 % by the end of the 23rd interview. No new codes
were applied in the last interview. The same process was
followed for caregivers and patients, including dyads
(N = 6).
3 Results
Thirty-eight caregivers of children/adolescents with ADHD
and 28 adolescents with ADHD originating from France,
Germany, Italy, the Netherlands, Norway, Spain, Sweden,
and the UK were interviewed. Of the caregivers, 74 %
were female, 30 % reported sharing the caregiving role
with a partner, and 26 % had earned a university degree.
Fifty-two percent were employed full- or part-time.
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The cohort of children/adolescents whose caregivers
were interviewed is presented in Table 1. The mean
(standard deviation [SD]) age of the cohort was 11.9
(3.7) years and 66 % were male. Thirty-four percent
were currently attending behavioral therapy sessions.
Twenty-five (66 %) children/adolescents were currently
taking stimulant medication, four (11 %) were taking
non-stimulant medication (atomoxetine), and four
(11 %) were on combination therapy. Five (13 %)
children/adolescents were not currently medicated.
Approximately half (53 %) of this cohort had no
comorbid conditions.
The adolescent cohort had a mean (SD) age of 15.3 (1.5)
years, 50 % were male, and all were currently on medi-
cation for ADHD (Table 2). Forty-three percent were
currently attending behavioral therapy sessions. Nineteen
(68 %) adolescents were currently taking stimulant medi-
cation, six (21 %) were taking non-stimulant medication,
and three (11 %) were on combination therapy. Seventy-
five percent of adolescents had no comorbid conditions.










































Female sex 13 (34) 3 (30) 3 (50) 2 (40) 1 (20) 1 (25) 1 (25) 0 2 (100)
Currently in behavioral
therapy
13 (34) 0 5 (83) 2 (40) 2 (40) 2 (50) 1 (25) 1 (50) 0
Current medication(s)
Methylphenidate 25 (66) 7 (70) 2 (33) 5 (100) 3 (60) 4 (100) 1 (25) 2 (100) 1 (50)
Atomoxetine 4 (11) 2 (20) 1 (17) 0 0 0 0 0 1 (50)
Combination 4 (11) 0 0 0 2 (40)a 0 2 (50)b 0 0
Not currently medicated 5 (13) 1 (10)c 3 (50) 0 0 0 1 (25) 0 0
ADHD type
Inattentive 10 (26) 2 (20) 2 (33) 2 (40) 0 0 2 (50) 1 (50) 1 (50)
Hyperactive/impulsive 12 (32) 4 (40) 3 (50) 1 (20) 2 (40) 1 (25) 0 1 (50) 0
Combined 6 (16) 1 (10) 0 1 (20) 0 2 (50) 1 (25) 0 1 (50)
Unknown 10 (26) 3 (30) 1 (17) 1 (20) 3 (60) 1 (25) 1 (25) 0 0
Comorbidity status
Without comorbidities 20 (53) 5 (50) 3 (50) 4 (80) 2 (40) 0 3 (75) 1 (50) 2 (100)
With comorbidities 16 (42) 5 (50) 3 (50) 1 (20) 3 (60) 3 (75) 1 (25) 0 0
Reported comorbidity, n
Aggression 4 1 0 0 0 2 1 0 0
Anxiety 6 3 1 0 1 1 0 0 0
Asperger syndrome 1 1 0 0 0 0 0 0 0
Conduct disorder 4 0 0 1 2 1 0 0 0
Depression 1 1 0 0 0 0 0 0 0
Learning disorder 7 1 3 0 1 2 0 0 0
Oppositional defiant
disorder
1 0 0 0 0 1 0 0 0
Sleep disorder 3 1 0 0 0 2 0 0 0
Speech/language
disorder
3 0 0 0 1 1 1 0 0
Missing data 2 (5) 0 0 0 0 1 0 1 0
Data are given as n (%) unless indicated otherwise
ADHD attention-deficit/hyperactivity disorder, SD standard deviation
a One participant on atomoxetine and methylphenidate, and another on atomoxetine and risperidone
b Immediate- and extended-release methylphenidate
c Previous experience with methylphenidate
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3.1 Key Themes of Unmet Needs
The key themes of potential unmet needs elicited from the
qualitative interviews are categorized into the following
domains: difficulties associated with diagnosis, presence of
ADHD symptoms on medication, difficulties with school
and psychosocial functioning, difficulties with home and
family life, treatment concerns, and caregiver-specific
concerns. These key themes were relevant across all eight
countries, all ages, and in both cohorts.
3.1.1 Difficulties Associated with Diagnosis
In general, caregivers reported that the process for
obtaining an ADHD diagnosis for their child was difficult.
Seventy-four percent of caregivers reported issues with
diagnosis, including lack of recognition of ADHD symp-
toms, lengthy waiting periods to receive specialist referrals,
misdiagnosis, and visits to multiple doctors. The time
frame for diagnosis ranged from a few months to several
years. For nine caregivers, it took C1 year to obtain an
ADHD diagnosis for their child and seven of these waited
C2 years for a diagnosis. In several instances, the care-
givers reported experiencing some blame for their child’s
symptoms and behaviors from healthcare providers before
an accurate diagnosis was reached, attributing the child’s
symptoms and behaviors to a poor parent–child relation-
ship or parenting issues.
Adolescents were not specifically asked about the pro-
cess of obtaining a diagnosis. However, 75 % expressed
concerns pertaining to the diagnosis, such as embarrass-
ment, shame and annoyance about having ADHD, being
Table 2 Sample characteristics for adolescent participants: total sample and by country







































Female sex 14 (50) 2 (40) 2 (50) 2 (50) 2 (50) 2 (50) 2 (50) 0 2 (100)
Currently in behavioral
therapy
12 (43) 1 (20) 4 (100) 1 (25) 2 (50) 2 (50) 1 (25) 0 1 (50)
Current medication(s)
Methylphenidate 19 (68) 5 (100) 0 4 (100) 1 (25) 4 (100) 3 (75) 1 (100) 1 (50)
Atomoxetine 6 (21) 0 4 (100) 0 1 (25) 0 0 0 1 (50)
Combination 3 (11) 0 0 0 2 (50)a 0 1 (25)b 0 0
ADHD type
Inattentive 3 (11) 0 0 0 1 (25) 2 (50) 0 0 0
Hyperactive/impulsive 5 (18) 0 2 (50) 0 0 1 (25) 2 (50) 0 0
Combined 7 (25) 3 (60) 1 (25) 0 1 (25) 1 (25) 1 (25) 0 0
Unknown 13 (46) 2 (40) 1 (25) 4 (100) 2 (50) 0 1 (25) 1 (100) 2 (100)
Comorbidity status
Without comorbidities 21 (75) 4 (80) 4 (100) 4 (100) 2 (50) 2 (50) 3 (75) 0 2 (100)
With comorbidities 6 (21) 1 (20) 0 0 2 (50) 2 (50) 1 (25) 0 0
Reported comorbidity, n
Anxiety 3 0 0 0 1 2 0 0 0
Conduct disorder 3 0 0 0 1 2 0 0 0
Eating disorder 1 0 0 0 0 1 0 0 0
Learning disorder 4 1 0 0 0 1 0 0 0
Oppositional defiant
disorder
0 0 0 0 0 1 0 0 0
Sleep disorder 1 0 0 0 0 1 1 0 0
Missing data 1 (4) 0 0 0 0 0 0 1 (100) 0
Data are given as n (%) unless indicated otherwise
ADHD attention-deficit/hyperactivity disorder, SD standard deviation
a One on atomoxetine and risperidone; another on extended- and immediate-release methylphenidate
b Extended- and immediate-release methylphenidate
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slower learners than their peers, and having more difficulty
understanding information, or being perceived by their
peers as ‘disabled’.
3.1.2 Presence of ADHD Symptoms on Medication
For the majority of the children/adolescents on medication,
both stimulant and non-stimulant alike, ADHD symptoms
were reduced, but not eliminated (Fig. 1). Eighty-eight
percent of caregivers reported that their child still contin-
ued to experience some core ADHD symptoms while on
medication. Similarly, all adolescents discussed experi-
encing impatience, difficulty concentrating, impulsivity,
hyperactivity, and/or verbal and physical aggression while
on medication.
3.1.3 Difficulties with School and Psychosocial
Functioning
Eighty-four percent of caregivers reported an impact on
school performance despite taking medication, resulting in
poor or failing grades. Approximately a third (37 %) of the
children/adolescents had been held back a year in school.
While adolescents generally reported that they could con-
centrate better at school when they took their medication,
all reported that even when taking medication they could
still be easily distracted, have difficulty focusing, or
become easily frustrated, which could lead to problems
with completing homework and exams.
ADHD symptoms not only affected academic progress
but also contributed to disciplinary problems at school, as
noted by a majority (71 %) of caregivers and many (64 %)
adolescents. Fifty-eight percent of caregivers reported that
disciplinary problems continued despite medication. Dis-
ciplinary problems resulted from behaviors such as fight-
ing, talking at inappropriate times, not finishing tasks,
inattention, getting to class late, missing school, and verbal
aggression with both classmates and teachers/administra-
tion, which are likely to represent undertreatment of
ADHD symptoms (Fig. 2).
Fifty percent of caregivers reported that their children
received special accommodations at school, such as extra
attention from teachers (13 %), special classes (18 %),
more time to complete assignments (5 %), individualized
assistance going over homework and notes (5 %), or less
homework (18 %), or attended a school for those with
special needs (16 %). Nevertheless, over half (52 %) of the
caregivers across all eight countries felt their educational
institutions were not fully informed about ADHD and the
best methods to educate and manage a child with the dis-
order. Over 50 % of adolescents conveyed a lack of
understanding of ADHD by their teachers and classmates,
or the feeling of being unsupported by their school. Care-
givers expressed a need for more sensitive and involved
teachers, smaller classes, more time to complete tasks,
after-school tutoring, and/or an assistant for one-on-one
help.
Almost 20 % of caregivers reported that their child
required accommodations in extracurricular activities,
including supervision during activities to make sure the
child remained safe or secure, or providing breaks to
compensate for restlessness or overstimulation.
Caregivers reported frustration with their child’s
inability to keep up with school work and connect with
others. They also reported that their child suffered emo-
tionally in coping with ADHD; 34 % reported their child/
Fig. 1 Remaining symptoms on medication. Adolescent and caregiver quotes regarding the continuation of symptoms while on medication. The
most frequently reported symptom remaining while on medication was ‘Inattention’
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adolescent experienced low self-esteem and a lack of
confidence, especially with regard to forming relationships.
Seventy-nine percent of caregivers reported that ADHD-
related behaviors affected their child/adolescents’ ability to
make and keep friendships. Some said their child found it
easier to be friends with younger children because of
emotional immaturity and that ADHD-related behaviors
limited their ability to participate in extra-curricular and
social activities. Others were concerned about their child
being easily manipulated by bad influences, and being
bullied (Fig. 3). Thirteen percent reported that their child
had no friends at all, and nearly 40 % that their child was
picked on or bullied by their peers and/or siblings because
of ADHD.
Adolescents reported that ADHD had a negative effect
on their interactions with friends and ability to be social,
and 75 % reported issues pertaining to social interactions
or forming new relationships. They limited social time to
close friends who they felt understood their ADHD, but
described feeling a need to be ‘careful’ around friends and
worried that they were ‘a lot to handle’.
3.1.4 Difficulties with Home and Family Life
Caring for a child with ADHD was reported to be very
demanding, requiring the caregivers to make accommo-
dations to meet their child’s needs. During a typical day,
extra time was required by caregivers to make sure the
child/adolescent was organized and focused enough to
complete simple daily tasks such as getting dressed, com-
pleting school assignments, and keeping track of belong-
ings. Some caregivers (39 %) noted the importance of
keeping the child to a routine and reported having to make
personal sacrifices to maintain the routine.
A number of caregivers reported limiting the types of
activities they participated in with their child/adolescent
with ADHD. Caregivers avoided taking the child shopping,
to social events, or public places where the child’s behavior
might cause disruptions. When attending social functions
with their child, they described often leaving early or
keeping to the edge of the crowd.
Additionally, both cohorts frequently reported that they
felt ADHD affected family relationships. Adolescents
reported arguing with their parents over incomplete
homework and poor school grades. Some caregivers felt
that their relationship with their child with ADHD was
different than the relationship they had with their other
children. They felt relationships with their children without
ADHD suffered from focusing more attention and super-
vision on the child with ADHD. Adolescents felt their
parents kept an overzealous eye on them because of their
behaviors or treated them differently than their siblings,
which sometimes caused problems between siblings.
Adolescents reported arguing with siblings, having diffi-
culty controlling outbursts of anger, and being sensitive to
teasing by their siblings about their ADHD. This was
Fig. 2 Difficulty with school. Adolescent and caregiver quotes on school-related difficulties associated with attention-deficit\hyperactivity
disorder. ‘Problems with exams/schoolwork’ was the most frequently reported issue for both cohorts
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supported by caregivers who reported situations where the
other sibling(s) treated the child with ADHD differently or
poorly as a result of the child’s behaviors owing to ADHD
(Fig. 4).
Thirty-nine percent of caregivers reported that their
child’s ADHD had an impact on their relationship with
their partner. For some, these difficulties stemmed from the
partner’s lack of acceptance or understanding of their
child’s ADHD diagnosis. A few (11 %) caregivers noted
that their child/adolescent’s ADHD did not negatively
impact their relationship with their partner, one of whom
noted that it had tightened the bond with their spouse.
3.1.5 Treatment Concerns
Caregivers reported a number of concerns about ADHD
medications, such as adverse effects (21 %), unknown
long-term adverse effects (26 %), the potential for depen-
dency or abuse (18 %), and cost (11 %). With regard to
behavioral therapy, a few caregivers (8 %) reported that it
was ineffective. No other concerns regarding non-phar-
macologic therapy were reported. When asked about their
current medication, 24 % reported an issue that their
child’s ADHD medication was no longer effective by the
afternoon, thereby making evenings at home particularly
difficult. For those whose children had stopped a medica-
tion in the past, adverse effects and decreased efficacy were
the primary reasons for discontinuing. Some (16 %) care-
givers reported either allowing their children to deviate
from their prescribed treatment regimen and take
medication ‘breaks’ or desiring to give their child medi-
cation breaks. This was generally related to concerns about
or experiences with adverse effects (Fig. 5).
Some adolescents noted increased feelings of ‘depres-
sion’ or low mood when the medication was no longer
effective at the end of the day and when describing a ‘bad
day’ on medication. Approximately 20 % of adolescents
reported that they felt their current ADHD medication
subdued them too much. Approximately 10 % felt their
medication affected their ability to fall asleep. Some
(11 %) adolescents were unhappy with having to take
medication ‘for such a long time’. Of particular concern for
some was the feeling of being ‘controlled by medications’
or losing their ‘self’ to medication.
Some adolescents noted feeling different than other
adolescents and/or had difficulty in determining what was
‘normal’ behavior. Some felt different than their peers
because they were required to take medication. They also
noted difficulty discerning whether their behavior was an
ordinary response to a situation or a result of their ADHD,
regardless of being on medication. The inability to know
whether their behavior was ‘normal’ or due to ADHD was
noted by one adolescent as making it difficult to gauge the
effectiveness of ADHD treatment.
3.1.6 Caregiver-Specific Impacts
Caregivers of children with ADHD felt stressed and wor-
ried that their child’s ADHD would negatively impact on
their future ability to be successful in school and work,
Fig. 3 Impact on activities and social life. Adolescent and caregiver quotes regarding the attention-deficit/hyperactivity disorder-related impacts
on a child’s social life and activities. ‘Difficulty with friendships’ was most commonly reported
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Fig. 4 Impact on family life, Adolescent and caregiver quotes
regarding attention-deficit/hyperactivity disorder-related impacts on
family relationships. While both the caregivers and adolescents
frequently reported the ‘Relationship between caregiver/child’ and
‘Relationship between siblings’ as important impacts on family life,
the caregivers frequently reported more general ‘Stress on the
household’
Fig. 5 Treatment concerns. Adolescent and caregiver quotes relating
to taking attention-deficit/hyperactivity disorder medication. While
caregivers were most concerned about ‘General concerns about taking
medication’, ‘Future/long-term effects’, and ‘adverse effects’, the
adolescents were most concerned about ‘efficacy’ and ‘adverse
effects’
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independent and accepted in society, and to keep off drugs
and out of danger. Caregivers of younger children worried
about how the disorder would present as the child became
an adolescent. Some caregivers reported their child might
engage in reckless or dangerous behavior, resulting in harm
to themselves or others.
Nearly half (47 %) of caregivers reported that having a
child/adolescent with ADHD adversely affected their
social lives. Decreased socializing resulted from not being
able to find a babysitter they could trust, friends and family
excluding them from events because of the child’s ADHD
behavior(s), or the caregivers excluding themselves over
concerns about their child being disruptive. Some felt these
difficulties were because of others’ lack of understanding
of ADHD or the stigma attached to the disorder.
Caregivers’ jobs and personal pursuits were also affec-
ted by their child’s ADHD. About 25 % of caregivers
reported having to reduce their working hours or stop
working entirely to be home to care for their child/ado-
lescent. Caregivers also had to make other sacrifices,
including giving up on personal pursuits, personal time,
and/or time alone with their partner.
Most caregivers (82 %) reported having to provide
almost constant supervision for their child/adolescent.
Caregivers had to supervise the completion of routine
tasks, the child/adolescent’s play and extracurricular
activities, in addition to general supervision to ensure the
child was safe. In general, caregivers reported feeling like
they always had to be ‘on alert’ or ‘on guard’ when it came
to caring for their child/adolescent and described the con-
stant need for supervision as one of the most difficult
aspects of having a child/adolescent with ADHD.
Caregivers also reported feeling exhaustion, a sense of
helplessness, guilt, and feeling both emotionally and
physically drained, and many (63 %) noted a need for
additional support and assistance from their healthcare
providers. Caregivers expressed that additional support
from doctors and/or through therapy would be helpful in
managing everyday issues related to their child’s ADHD.
Caregivers relayed a need for more government support, in
areas such as social, education, and health services, and
financial assistance and education for caregivers, teachers,
and the general public.
3.2 Dyad Analysis: Caregiver vs. Adolescent Reports
A total of six caregiver/adolescent dyads completed inter-
views. In general, there was good agreement between
adolescents and their caregivers regarding impacts of
ADHD. The adolescents in the dyad group displayed self-
awareness, as evidenced by the consistency of responses
between caregivers and adolescents on themes related to
school, medication adverse effects, and symptoms not fully
treated by the ADHD medication. The adolescents in the
dyad group displayed less agreement with their caregivers
with respect to accommodations made for them (e.g., extra
assistance with homework or classwork); concerns, dis-
likes, and desired changes to ADHD medications; and
reasons that past ADHD medications were stopped. Areas
of discordance (i.e., where the concept was only reported
by one of the individuals in the dyad) included the desire
for the medication to control symptoms better (3/6 dyads
were discordant), have fewer adverse effects (2/6 dyads
were discordant), and last longer (2/6 dyads were discor-
dant). In both cases of discordance for wanting fewer
adverse effects, it was the adolescent who specifically
reported wanting fewer adverse effects. For the other areas
of discordance, no pattern emerged.
4 Discussion
Current ADHD treatment, pharmacologic and non-phar-
macologic, is helpful but caregivers clearly report signif-
icant unmet needs with the current standard of care. This
study identified concepts where unmet need might remain
despite ADHD treatment for both children/adolescents
with ADHD and their caregivers in the participating
European countries. Current treatments help to reduce, but
do not fully alleviate symptoms and have variable effec-
tiveness over the course of the day. Persistence of
symptoms may lead to underperformance and disciplinary
issues at school, problems with social interactions and
friendships, strained relationships among family members,
and emotional issues, such as low self-esteem. Caregivers
face significant burdens as well. They spend a substantial
amount of time and effort helping their child manage their
illness and dealing with the consequences of their child’s
behavior. Furthermore, caregivers of children on treatment
continue to worry and feel stress, specifically with regard
to potentially disruptive and dangerous behaviors, per-
formance in school, long-term effects of medication, and
their child’s future. Thus, even with current management,
this suggests that ADHD may impose a great burden on
children/adolescents and their caregivers. This finding is
consistent with the results of a caregiver survey in which
children who were medicated still experienced substantial
challenges, particularly with respect to family relation-
ships [19].
A common issue reported by caregivers and adolescents
alike, is that medication is generally effective only during
school hours. The result is that caregivers tend to bear the
brunt of the child’s ADHD, outside of school hours, when
the child is not medicated. Caregivers in our study reported
feelings of exhaustion, helplessness, being overwhelmed
because of the demands of caring for a child with ADHD,
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and conflicts at home among family members related to the
child’s ADHD.
Despite the fact that participants reported persistent
symptoms and impacts associated with ADHD, most par-
ticipants acknowledged seeing a substantial difference in
behavior when on versus off medication and noted that
medication had improved their lives.
Adolescent interviews did not elicit any new issues that
had not been elicited through the caregiver interviews. The
adolescents in this sample displayed a general self-aware-
ness of the symptoms, behaviors, and impacts associated
with their ADHD, recognizing, for example, their chal-
lenges with social interactions and the fact that their
ADHD impacts their family. This is contrary to other
studies, which have demonstrated that adolescents are in
general less self-aware of issues with peer and family
interactions [20].
While studies related to patient and caregiver burdens
associated with ADHD have been conducted, there is
limited literature exploring this burden while the patient is
on treatment. Nevertheless, a few studies support the
findings seen here. A Swedish study conducted by Svan-
borg and colleagues [21] explored the impact of treatment
on patient and family coping and found that, although
atomoxetine benefited children in some areas, it failed to
improve patients’ self-image and caregivers’ perceptions
regarding family dynamics. Two recent studies support our
finding that having a child with ADHD impacts family
relationships [14, 15]. Both studies report that caregivers of
a child with ADHD are more likely to divorce than those
without. A recent UK study to explore correlates of care-
giver unmet needs for those caring for adolescents and
young adults with ADHD found that the domains most
associated with caregiver burden were depression/anxiety
and inappropriate behavior [13].
In addition to unmet needs related to symptom control,
caregivers commonly reported a lack of support and
understanding from school, the health system, and/or the
community at large. Some expressed frustration regarding
the lengthy diagnosis process, as well as having limited
access to healthcare or support services.
Our study findings suggest that comprehensive care
plans that include patient and caregiver support from the
education and healthcare systems and additional counsel-
ing alongside pharmacologic management result in better,
more consistent, and longer-lasting symptom control that
may help reduce the negative quality of life impact on
children/adolescents and caregivers.
This study has some limitations. The participants were
volunteers recruited through patient panels and may not be
representative of the entire ADHD population in the
selected countries. While the goal of concept elicitation is
to reach information saturation, which we attained for the
sample overall, we did not assess saturation at the country
level as sample sizes per country were generally small.
Thus, we were unable to draw conclusions regarding
potential country-specific differences relating to unmet
needs, rather just the overall concepts across these eight
countries. Additionally, as ADHD is a highly comorbid
disorder, this study is also limited because of the exclusion
of children and adolescents with severe comorbidities that
could have a major impact on their quality of life, such as
schizophrenia or bipolar disorder. While our sample may
not be generalizable to the ADHD population with com-
orbidites, it was our desire to focus on unmet needs spe-
cifically related to ADHD without the influence and
confounding effects of other disorders. With this goal in
mind, having any comorbid condition was initially a cri-
terion for exclusion; however, owing to difficulties in
meeting recruitment targets, this criterion was relaxed prior
to initiating any interviews. Inclusion priority was then
given to patients with no, few, or less severe comorbid
conditions, such as learning disorders, speech disorders,
sleep disorders, or oppositional defiant disorder. In our
study population, six (21 %) adolescents and 16 (42 %)
children of the caregivers sample did have comorbidities.
In these cases, we requested that participants focus only on
impacts associated with ADHD, but they may have had
difficulty attributing specific impacts to ADHD vs. their
other conditions. It is likely that children and young people
with severe and complex comorbidities have even greater
unmet needs.
5 Conclusions
Available ADHD treatments in the EU have been shown as
effective at reducing symptoms and improving the lives of
children/adolescents and their caregivers. However, some
patients and their caregivers in this study described areas of
unmet need, despite receiving treatment in many cases. In
this sample, the impact in children/adolescents was most
notable with regard to school performance and interper-
sonal relationships. For caregivers, the demands and stress
associated with raising a child with ADHD take a toll on
relationships with family members and friends, as well as
their career. Caregivers also worried about the implications
of long-term pharmacologic treatment as well as about
their child’s future well-being and ability to be successful
in life. Caregivers reported a general lack of education and
support within their communities, and they expressed a
desire for additional support from the healthcare commu-
nity in managing their child’s condition and coping with
everyday life. Service providers should consider ways of
using more comprehensive multimodal treatments to
potentially reduce the negative impacts of ADHD.
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Based on the interview findings, the web-based Care-
giver Perspective on Paediatric ADHD (CAPPA) survey
has been developed. CAPPA will aim to validate and
quantify the findings of this study among a larger sample
and to further understand the impacts on children/adoles-
cents with ADHD and their caregivers in several European
countries. The ultimate aim will be to more broadly and
quantitatively collect, understand, and analyze the burden
of ADHD to potentially inform providers of how patient
care can be improved and to minimize the impact of
ADHD on the lives of children/adolescents and their
caregivers, whether through additional and/or more effec-
tive treatments, further caregiver and community educa-
tion, or more community support. While many of the issues
faced by caregivers and their children with ADHD may not
have easy solutions, information gathered through the
CAPPA study may shed light on what steps can and should
be taken to improve the quality of life of these patients and
their caregivers. The insights provided by CAPPA
regarding the perceived needs of patients and caregivers
may improve patient/caregiver and provider communica-
tion and facilitate the identification of new solutions to
optimize the provision of care.
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